Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Official Title

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Summary:

This is a study of genetically engineered ADP-A2M4 in HLA-A*02 subjects with metastatic or inoperable (advanced) Synovial Sarcoma or MRCLS who have received prior chemotherapy and whose tumour expresses the MAGE-A4 tumour antigen.

Trial Description

Primary Outcome:

  • Efficacy: Overall Response Rate (ORR)
Secondary Outcome:
  • Number of subjects with treatment -related adverse events (AEs), including serious adverse events (SAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
  • Evaluate safety of ADP-A2M4 through measurement of Replication -competent Retrovirus in genetically engineered T-cells
  • Measurement of T-cell clonality and insertional oncogenesis in peripheral blood mononuclear cells (PBMCs).
  • Efficacy: Best overall response (BOR)
  • Time to response (TTR)
  • Duration of Response (DoR)
  • Progression Free Survival (PFS)
  • Overall Survival (OS)
  • Quantitation of genetically engineered T-cells in PBMCs
  • Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs
  • Quantitation of genetically engineered T-cells in PBMCs
  • Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs
  • Invitro diagnostic (IVD) assay for screening

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society